669. Twelve-Month Durability of Microbiota-Based Therapy RBX2660 for Prevention of Recurrent Clostridium difficile Infection

BACKGROUND: Recurrent Clostridium difficile infections (rCDI) are a public health threat with insufficient treatment options at present. Two Phase 2 clinical studies have reported the efficacy of RBX2660, a standardized, stabilized microbiota-based drug, in preventing rCDI. For one of these trials,...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Courtney, Mische, Sarah, Blount, Ken, Shannon, Bill
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811224/
http://dx.doi.org/10.1093/ofid/ofz360.737

Ejemplares similares

Ejemplares similares